Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Lexaria Bioscience Corp.
  4. Financial Statements
  5. Income Statement
Lexaria Bioscience Corp. logo
Lexaria Bioscience Corp. LEXX
$ 2.86 3.68%
report update icon

Quarterly report 2026-Q3
added 07-13-2026

Lexaria Bioscience Corp. Income Statement 2025-2009 | LEXX

Annual Income Statement Lexaria Bioscience Corp.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

 19.1 M 33.5 M 10.1 M 7.44 M 17.6 M - - - - - - - - - - - -

Shares

 19.6 M 15.8 M 8.09 M 5.95 M 4.39 M - - - - - - - - - - 12.9 M -

Historical Prices

 0.977 2.12 1.25 1.25 4.03 - - - - - - - - - - - -

Net Income

 -11.9 M -5.8 M -6.66 M -7.27 M -4.19 M - - - - - - - - - - -552 K -

Revenue

 706 K 464 K 226 K 255 K 723 K - - - - - - - - - - - -

Cost of Revenue

 2.72 K 4.82 K 31.5 K 71.8 K 175 K 99.4 K 22.9 K 25.2 K 29.8 K 45.6 K - - 795 K 783 K 668 K 274 K -

Gross Profit

 703 K 459 K 195 K 184 K 547 K - - - - - - - - - - 88.9 K -

Operating Income

 -11.9 M -5.75 M -6.53 M -6.62 M - - - - - -1.28 M -1.98 M -1.56 M - - - - -

Interest Expense

 - -55.5 K -179 K -765 K - - - - 6.02 K 2.25 K 31.5 K 166 K 267 K 238 K 224 K 167 K -

EBITDA

 -11.8 M -5.71 M -6.39 M -6.52 M 112 K - - - - - - - - - - 1.02 K -

Operating Expenses

 12.6 M 6.21 M 6.73 M 6.8 M 6.23 M - - - - - - - - - - 641 K -

General and Administrative Expenses

 4.35 M 3.85 M 3.06 M 4.96 M 4.97 M - - - - - - - - - - 1.21 K -

All numbers in USD currency

Quarterly Income Statement Lexaria Bioscience Corp.

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 24.8 M 24.9 M 24.9 M 22.2 M 19.5 M 19.5 M 17.4 M 17.5 M 19.6 M 15.8 M 12.4 M 10.3 M 8.09 M 8.09 M 5.95 M 5.95 M 5.95 M 5.95 M 5.91 M 5.73 M 5.73 M 5.1 M 4.05 M 3 M 2.7 M 2.77 M 3 M 2.64 M 77.5 M 80.6 M 79.1 M 76.2 M 70.2 M 71 M 76.2 M 68.6 M 56 M 60.6 M 68.6 M 51.7 M 42.9 M 45 M 51.7 M 43.9 M 38.4 M 39.1 M 39.9 M 23.4 M 16.4 M 16.4 M 23.4 M 16.4 M 16.4 M 16.4 M 16.4 M 16.4 M 16.4 M 16.4 M 16.4 M - 13.5 M 14.3 M 16.4 M

Net Income

 -1.99 M -1.45 M -1.45 M -1.6 M -3.79 M -3.79 M -2.71 M -2.7 M - -1.78 M -650 K -1.18 M - -2.37 M -1.3 M -1.76 M - -2.38 M -1.43 M -1.99 M -1.18 M -2.57 M -2.56 M -710 K 3.9 M -1.39 M -710 K -925 K -3.04 M -1.85 M -925 K -701 K -5.38 M -1.96 M -701 K -579 K -1.21 M -1.87 M -1.87 M -395 K -1.21 M -1.21 M -395 K -412 K -1.25 M -468 K -382 K -398 K - - -347 K -75.5 K - - - -119 K - - -232 K -130 K - -253 K -156 K

Revenue

 - 20 K 20 K - 174 K 174 K 174 K 184 K - 84 K 145 K 151 K - 93.2 K 35 K 101 K - 99.7 K 30.6 K 13.9 K 692 K 204 K 192 K 296 K 251 K 36.4 K 37.5 K 10.3 K 97.5 K 59.9 K 62.1 K 22.2 K 337 K 140 K 172 K 24.6 K 51.1 K 29.3 K 12.6 K 9.22 K 32.2 K 6.22 K 15.2 K - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

 - - - - - - - 2.72 K - - - 4.82 K - 12.7 K 2.96 K 15.8 K - 18.6 K 6.39 K 5.57 K 155 K 60 K 30.6 K 64.5 K 86.3 K 20.3 K 64.5 K 7.85 K 7.94 K 3.1 K 7.85 K 2.16 K 22.2 K 2.43 K 2.16 K 6.1 K - - - - - - - 14.4 K - 9.69 K 2.05 K - - - - 223 K - 175 K 165 K 145 K 518 K 229 K 143 K 211 K 576 K 153 K 212 K

Gross Profit

 - 20 K 20 K - 174 K 174 K 174 K 181 K - 84 K 145 K 146 K - 80.4 K 32.1 K 85.7 K - 81.1 K 24.3 K 8.31 K 537 K 144 K 161 K 231 K 165 K 16.1 K 231 K 2.48 K 89.5 K 56.8 K 54.2 K 20.1 K 315 K 138 K 20.1 K 18.5 K 26.1 K 20.1 K 18.5 K 8.34 K -10.8 K -3.09 K 8.34 K -3.6 K -1.67 K -2.5 K -3.6 K - - - - 128 K - 76.2 K 88.3 K 104 K 371 K 265 K 1.72 K 51 K 301 K 174 K 75.8 K

Operating Income

 -1.99 M -1.45 M -1.45 M -1.57 M -3.75 M -3.75 M -2.75 M -2.69 M - -1.74 M -668 K -1.14 M - - - - - -2.42 M - - -4.38 M -2.57 M - - - - - - - - - - - - - -579 K - -866 K - -401 K - -264 K -275 K -412 K -1.37 M -511 K -459 K -398 K - -568 K - - -57.7 K -57.7 K - - - - - - - - -

Interest Expense

 - - - - - - - -15.9 K - -41.4 K 15.3 K -45.9 K - - - - - - - - - - - - - - - - - - - - - - - - 4.89 K 1.58 K 1.95 K 1.36 K 1.12 K 1.05 K 1.36 K 77 31.5 K - 77 31.5 K 162 K 53.1 K 31.5 K 116 K 267 K 41.7 K 50.2 K 53.1 K 172 K 58.8 K 59.9 K 56.9 K 172 K 57.6 K 57.8 K

EBITDA

 -1.95 M -1.43 M - -1.56 M -3.71 M - - -2.68 M - - - -1.11 M - - - 24.7 K - -2.42 M - 27.9 K -4.3 M -2.54 M 27.9 K 27.9 K 83.9 K 28.1 K 27.9 K 27.5 K 34.4 K 22.7 K 27.5 K 1.6 K 1.36 K 527 1.6 K -578 K 1.12 K -865 K 375 -400 K 464 -264 K -274 K -412 K -1.37 M -511 K -459 K -398 K - -568 K - - -57.7 K -57.7 K - - - - - 255 425 - 170

Operating Expenses

 1.99 M 1.47 M 1.47 M 1.57 M 3.92 M 3.92 M 2.93 M 2.87 M - 1.83 M 813 K 1.29 M - 2.46 M 1.34 M 1.85 M - 2.5 M 1.47 M 2.01 M 4.92 M 2.71 M 1.27 M 944 K 3.45 M 1.43 M 1.04 M 979 K 3.13 M 1.24 M 979 K 721 K 5.7 M 3.56 M 721 K 597 K 1.24 M 364 K 597 K 409 K 940 K 261 K 409 K 408 K 1.37 M 509 K 408 K 398 K 797 K 528 K 398 K 240 K 627 K 134 K 136 K 223 K 654 K 197 K 234 K 181 K 840 K 427 K 232 K

General and Administrative Expenses

 1.02 M 997 K 997 K 902 K 1.21 M 1.21 M 1.24 M 919 K - 1.25 M 567 K 711 K - 823 K 647 K 1.03 M - 1.75 M 1.2 M 1.55 M 4.1 M 2.26 M 1.09 M 752 K 194 K 55.4 K 76.5 K 74 K 207 K 81.9 K 74 K 72.9 K 183 K 64.8 K 72.9 K 46.2 K 112 K 41.6 K 35.8 K 23.4 K 10.7 K 2.05 K 2.91 K 4.04 K 19.8 K 8.74 K 4.04 K 5.62 K 8.22 K 7.04 K 5.62 K 4.18 K 6.76 K 410 1.87 K 1.13 K 2.28 K 628 524 1.42 K 4.28 K 2.27 K 592

All numbers in USD currency

The income statement is one of the three key financial reports of a company Lexaria Bioscience Corp. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.